0001062993-24-001086.txt : 20240119
0001062993-24-001086.hdr.sgml : 20240119
20240119163333
ACCESSION NUMBER: 0001062993-24-001086
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240117
FILED AS OF DATE: 20240119
DATE AS OF CHANGE: 20240119
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Shankar Gopi
CENTRAL INDEX KEY: 0001965014
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36510
FILM NUMBER: 24546056
MAIL ADDRESS:
STREET 1: C/O LARIMAR THERAPEUTICS, INC.
STREET 2: THREE BALA PLAZA EAST. SUITE 506
CITY: BALA CYNWYD
STATE: PA
ZIP: 19004
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Larimar Therapeutics, Inc.
CENTRAL INDEX KEY: 0001374690
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 203857670
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: THREE BALA PLAZA EAST. SUITE 506
CITY: BALA CYNWYD
STATE: PA
ZIP: 19004
BUSINESS PHONE: 844-511-9056
MAIL ADDRESS:
STREET 1: THREE BALA PLAZA EAST. SUITE 506
CITY: BALA CYNWYD
STATE: PA
ZIP: 19004
FORMER COMPANY:
FORMER CONFORMED NAME: ZAFGEN, INC.
DATE OF NAME CHANGE: 20100301
FORMER COMPANY:
FORMER CONFORMED NAME: ZAFGEN INC
DATE OF NAME CHANGE: 20060906
4
1
form4.xml
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
X0508
4
2024-01-17
0001374690
Larimar Therapeutics, Inc.
LRMR
0001965014
Shankar Gopi
C/O LARIMAR THERAPEUTICS, INC.
THREE BALA PLAZA EAST, SUITE 506
BALA CYNWYD
PA
19004
0
1
0
0
Chief Development Officer
0
Common Stock
2024-01-17
4
A
0
22500
0.00
A
27500
D
Stock Option (Right to Buy)
4.21
2024-01-17
4
A
0
135000
0.00
A
2034-01-17
Common Stock
135000
135000
D
Each share is represented by a restricted stock unit ("RSU"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock upon settlement.
The option vests 25% on January 17, 2025, with the remaining 75% vesting in equal monthly installments on the last day of each of the 36 calendar months immediately following such date, subject to the Reporting Person's continued service with the Issuer through the applicable vesting date.
/s/ Jennifer Johansson, Attorney-in-fact
2024-01-19